Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 5Unknown 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 3Other solid neoplasm 1Dermatologic 1

Conditions

Brain Neoplasms 3Neoplasm Metastasis 2Glioblastoma 2Refractory Solid Tumors 1Recurrence 1Melanoma 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × INDUSTRY × verubulin × Clear all
NCT01285414 2012-04-11

Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

Myrexis Inc.

Phase 2 Completed
5 enrolled
CNS

Brain Neoplasms, Glioblastoma

NCT00892931 2011-10-14

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

Myrexis Inc.

Phase 2 Completed
56 enrolled
CNS

Brain Neoplasms, Glioblastoma, Recurrence

NCT00609011 2010-08-23

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

Myrexis Inc.

Phase 1/2 Completed
22 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00393965 2008-02-13

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

Myrexis Inc.

Phase 1 Completed
18 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT00394446 2008-02-13

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

Myrexis Inc.

Phase 1 Completed
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡